United States President Donald Trump unveiled a new government-backed online platform called TrumpRx.gov on Thursday, February 5, 2026, during a White House event, promising Americans significantly lower prices on dozens of commonly prescribed medications, including high-cost GLP-1 weight-loss drugs and fertility treatments.
Speaking from the White House briefing room, Trump described the initiative as a direct response to what he called decades of Americans paying “far more” for prescription drugs than consumers in other countries. “Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers,” he declared. “We’re bringing drug prices down like never before, and it’s happening fast.”
The TrumpRx platform functions as a centralized portal that connects patients directly to manufacturer-sponsored discount programs. Users can search for their specific medication, generate a printable discount coupon, and present it at participating pharmacies nationwide to receive the reduced price. The White House said the site launched with discounts on more than 40 popular prescription drugs, covering treatments for diabetes, hypertension, cholesterol, pain management, and other chronic conditions.
A major focus of the announcement was access to GLP-1 receptor agonists, the class of medications that includes semaglutide (marketed as Ozempic by Novo Nordisk and Wegovy by Novo Nordisk) and tirzepatide (Mounjaro and Zepbound by Eli Lilly). These drugs, originally developed for type 2 diabetes, have surged in popularity for their substantial weight-loss effects, but their list prices—often exceeding $1,000 per month without insurance—have made them inaccessible to many.
Under the TrumpRx agreements, Novo Nordisk has committed to offering Ozempic and Wegovy at $199 per month for the first two months, after which prices will gradually rise but remain below original list prices. Eli Lilly has similarly agreed to provide steep discounts on its GLP-1 offerings. Administration officials said these reductions were achieved through direct negotiations that leveraged the president’s “Most Favored Nation” (MFN) pricing policy, which ties US drug prices to the lowest rates offered in other developed countries.
Trump also highlighted fertility treatments as a priority. During the event, officials introduced a woman identified as the first user of the platform, who accessed a reduced-cost fertility medication through TrumpRx. Mehmet Oz, the television personality currently serving as Administrator of the Centers for Medicare & Medicaid Services (CMS), told the audience that lower prices on fertility drugs could dramatically increase access to treatments such as in vitro fertilization (IVF) medications, potentially boosting birth rates among American families.
The initiative forms part of a broader push by the Trump administration to address rising living costs as the country approaches the November 2026 midterm elections. With Republicans currently holding narrow majorities in both the House and Senate, party strategists have expressed concern that voter dissatisfaction over inflation, healthcare costs, and economic pressures could lead to losses in Congress. Trump has repeatedly warned that a Democratic takeover would expose him to renewed impeachment efforts, heightening the political stakes around his economic agenda.
In recent months, the president has secured a series of pricing agreements with major pharmaceutical companies, including Eli Lilly, Novo Nordisk, Pfizer, and Johnson & Johnson. These deals reportedly include incentives for drugmakers—such as relief from certain tariffs imposed during the administration—in exchange for adopting MFN-style pricing and expanding patient assistance programs. The White House has also applied pressure on foreign governments, notably Britain and France, to align their pharmaceutical pricing with US demands, a move that has caused diplomatic friction. French President Emmanuel Macron has publicly criticized the approach as “coercive.”
Although Trump previously downplayed affordability concerns during his campaign and early second term, his recent focus on lowering consumer costs reflects shifting political realities. Polling shows his approval ratings on the economy remain soft, and Republicans fear that persistent high prices for essentials—including prescription drugs—could motivate turnout against the party in the midterms.
The TrumpRx platform is not a new government insurance program or price-control mechanism but rather a facilitation tool that aggregates existing manufacturer discounts and coupons. Administration officials stressed that the site is open to all Americans, regardless of insurance status, and does not require enrollment in any federal program. Pharmacies have been instructed to honor the printed coupons, with participating chains including major retail and chain pharmacies.
Critics, including some Democratic lawmakers and healthcare advocates, have questioned the long-term sustainability of the discounts and warned that initial low introductory prices could rise sharply after the promotional period. Others have raised concerns about the potential for drugmakers to recoup costs through higher list prices elsewhere or reduced investment in research and development.
Supporters, however, hailed the move as a tangible win for consumers, particularly those without comprehensive insurance coverage or high deductibles. The White House said more drugs would be added to the platform in the coming weeks, with ongoing negotiations aimed at expanding the list further.
As the 2026 midterm campaign intensifies, the launch of TrumpRx.gov represents a high-profile effort by the administration to demonstrate progress on pocketbook issues and blunt criticism over economic management.
